Background & Aims As more treatment options for inflammatory bowel diseases become
available, it is important to identify patients most likely to respond to different therapies. We …

Abstract Background and Aims Vedolizumab (VDZ) is effective for Crohn's disease (CD) but
costly and is slow to produce remission. Early knowledge of whether vedolizumab is likely to …

Background The efficacy of vedolizumab, an α4β7 integrin antibody, in Crohn's disease is
unknown. Methods In an integrated study with separate induction and maintenance trials …

Background Cohort studies have described the short‐term effectiveness and safety of
vedolizumab in treating patients with Crohn's disease (CD) and ulcerative colitis (UC), but …

Background Direct comparisons are lacking between vedolizumab and tumour necrosis
factor (TNF)‐antagonist therapy in Crohn's disease (CD). Aim To compare safety and …

Background Vedolizumab is a gut-selective α4β7 integrin antagonist for the treatment of
moderately to severely active Crohn's disease (CD). Aims of this study were to characterize …

Background & Aims We evaluated the ability of vedolizumab to induce endoscopic and
histologic remission in patients with Crohn's disease (CD). Methods We performed a …

Background & Aims Vedolizumab is a gut-selective monoclonal antibody for the treatment of
moderately to severely active Crohn's disease (CD). We performed a prospective study of …

Background A clinical decision support tool (CDST) has been validated for predicting
treatment effectiveness of vedolizumab (VDZ) in Crohn's disease. Aim To assess the utility of …

Background & Aims Vedolizumab is effective and safe for the treatment of Crohn's disease
(CD) and ulcerative colitis (UC). Little is known about the incidence rate of loss of response …